aclarubicin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics, daunorubicin derivatives 80 57576-44-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aclacinomycin
  • Aclacinomycin A
  • aclacur
  • aclarubicin
  • Antibiotic 3082A
  • aclarubicin hydrochloride
  • aclarubicin HCl
An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.Aclarubicin is evaluated for the treatment of different conditions like acute myeloid leukemia, thyroid cancer, gastric cancer, lymphoma, small cell lung cancer. It is an inhibitor of topoisomerase II inhibitor being used in combination with different anticancerous drugs to obtain best therapeutic results and to reduce toxicity or side effects.
  • Molecular weight: 811.88
  • Formula: C42H53NO15
  • CLOGP: 3.37
  • LIPINSKI: 2
  • HAC: 16
  • HDO: 4
  • TPSA: 217.05
  • ALOGS: -3.57
  • ROTB: 10

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bone marrow failure 120.48 66.61 26 158 27598 50577342

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bone marrow failure 120.31 57.91 28 138 27421 29546940

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bone marrow failure 229.69 77.25 54 355 47898 64450425

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01DB04 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Anthracyclines and related substances
MeSH PA D000276 Adjuvants, Immunologic
MeSH PA D000903 Antibiotics, Antineoplastic
MeSH PA D000970 Antineoplastic Agents
MeSH PA D007155 Immunologic Factors
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:50750 inhibitors of type II topoisomerase
CHEBI has role CHEBI:68495 Type I cell-death inducers
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D059005 Topoisomerase II Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute myeloid leukemia, disease indication 91861009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.01 acidic
pKa2 9.34 acidic
pKa3 8.65 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
DNA topoisomerase 1 Enzyme INHIBITOR KEGG DRUG KEGG DRUG
DNA topoisomerase II Enzyme INHIBITOR KEGG DRUG KEGG DRUG
5-hydroxytryptamine receptor 2B GPCR Ki 6.15 DRUG MATRIX
72 kDa type IV collagenase Enzyme IC50 5 CHEMBL

External reference:

IDSource
N0000168464 NUI
D01911 KEGG_DRUG
239 RXNORM
C0001143 UMLSCUI
CHEBI:74619 CHEBI
CHEMBL502620 ChEMBL_ID
D015250 MESH_DESCRIPTOR_UI
DB11617 DRUGBANK_ID
C011157 MESH_SUPPLEMENTAL_RECORD_UI
4945 INN_ID
75443-99-1 SECONDARY_CAS_RN
74KXF8I502 UNII
451415 PUBCHEM_CID
003919 NDDF
003920 NDDF
CHEMBL1697719 ChEMBL_ID
326830005 SNOMEDCT_US
391713006 SNOMEDCT_US
391714000 SNOMEDCT_US

Pharmaceutical products:

None